CVM
Price
$8.94
Change
-$0.31 (-3.35%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
47.5M
EYPT
Price
$10.92
Change
+$0.86 (+8.55%)
Updated
Aug 5, 04:59 PM (EDT)
Capitalization
692.25M
One day until earnings call
Interact to see
Advertisement

CVM vs EYPT

Header iconCVM vs EYPT Comparison
Open Charts CVM vs EYPTBanner chart's image
Cel-Sci
Price$8.94
Change-$0.31 (-3.35%)
Volume$1.6K
Capitalization47.5M
EyePoint Pharmaceuticals
Price$10.92
Change+$0.86 (+8.55%)
Volume$8.38K
Capitalization692.25M
CVM vs EYPT Comparison Chart in %
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. EYPT commentary
Aug 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 05, 2025
Stock price -- (CVM: $9.25 vs. EYPT: $10.06)
Brand notoriety: CVM: Notable vs. EYPT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 34% vs. EYPT: 93%
Market capitalization -- CVM: $47.5M vs. EYPT: $692.25M
CVM [@Biotechnology] is valued at $47.5M. EYPT’s [@Biotechnology] market capitalization is $692.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than CVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 5 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • CVM’s TA Score: 5 bullish, 4 bearish.
  • EYPT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CVM is a better buy in the short-term than EYPT.

Price Growth

CVM (@Biotechnology) experienced а +7.43% price change this week, while EYPT (@Biotechnology) price change was +0.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.39%. For the same industry, the average monthly price growth was +19.63%, and the average quarterly price growth was +13.22%.

Reported Earning Dates

CVM is expected to report earnings on May 15, 2025.

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($692M) has a higher market cap than CVM($47.5M). EYPT YTD gains are higher at: 35.034 vs. CVM (-22.897). CVM has higher annual earnings (EBITDA): -21.96M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. CVM (1.92M). CVM has less debt than EYPT: CVM (10.5M) vs EYPT (24.1M). EYPT has higher revenues than CVM: EYPT (56M) vs CVM (0).
CVMEYPTCVM / EYPT
Capitalization47.5M692M7%
EBITDA-21.96M-144.55M15%
Gain YTD-22.89735.034-65%
P/E RatioN/AN/A-
Revenue056M-
Total Cash1.92M318M1%
Total Debt10.5M24.1M44%
FUNDAMENTALS RATINGS
CVM vs EYPT: Fundamental Ratings
CVM
EYPT
OUTLOOK RATING
1..100
372
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3443
P/E GROWTH RATING
1..100
5519
SEASONALITY SCORE
1..100
40n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVM's Valuation (50) in the Biotechnology industry is in the same range as EYPT (50) in the Pharmaceuticals Major industry. This means that CVM’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (87) in the Pharmaceuticals Major industry is in the same range as CVM (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to CVM’s over the last 12 months.

EYPT's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CVM (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to CVM’s over the last 12 months.

CVM's Price Growth Rating (34) in the Biotechnology industry is in the same range as EYPT (43) in the Pharmaceuticals Major industry. This means that CVM’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for CVM (55) in the Biotechnology industry. This means that EYPT’s stock grew somewhat faster than CVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMEYPT
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 19 days ago
86%
Declines
ODDS (%)
Bearish Trend 30 days ago
90%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGPMX31.01N/A
N/A
Franklin Gold and Precious Metals R6
DHIAX19.43N/A
N/A
Diamond Hill International Inv
FSYKX10.09N/A
N/A
Fidelity Advisor Sustainable EM Eq C
GCVTX23.51N/A
N/A
Goldman Sachs Large Cp Val Insghts Inv
JBAFX30.35N/A
N/A
JHancock Balanced R4

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+3.60%
OCUL - EYPT
65%
Loosely correlated
+3.61%
LYRA - EYPT
58%
Loosely correlated
+3.80%
BEAM - EYPT
54%
Loosely correlated
+1.54%
RXRX - EYPT
54%
Loosely correlated
+2.11%
ATHE - EYPT
54%
Loosely correlated
+3.58%
More